Navigation Links
FDA: Procter & Gamble Unlawfully Marketing Two Vicks Cold and Flu Medicines Containing Vitamin C
Date:10/30/2009

SILVER SPRING, Md., Oct. 30 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today sent a warning letter to Procter & Gamble notifying the company that its Vicks DayQuil Plus Vitamin C and Vicks Nyquil Plus Vitamin C are illegally marketed combinations of drug ingredients and a dietary ingredient.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO )

Both of the over-the-counter (OTC) medicines, which contain vitamin C in addition to several drug ingredients, are marketed as treatments for cold and flu symptoms. The FDA took the action against the Cincinnati-based company:

  • To clarify that these single dosage form combinations of drug ingredients and dietary ingredients legally cannot be marketed because they have not been proven safe and effective, and
  • Because the agency previously determined that there are insufficient data to show that vitamin C is safe and effective in preventing or treating the common cold.

Under its OTC monograph system, the FDA allows some OTC drugs to be marketed without agency approval. Such drugs must comply with applicable monographs, which are regulations that set requirements for the drugs' labeling, formulations and indications. The two Vicks products do not comply with the applicable FDA monograph and must first be evaluated and approved under the FDA's new drug approval process to be legally marketed.

The FDA's position on the regulatory status of OTC drug products that combine drug ingredients with dietary ingredients in a single dosage form has been described in previous warning letters issued in 2001 and 2008. The agency's position on the marketing of vitamin C for preventing or treating the common cold also has been stated in a number of previous warning letters.

(Editor's note: The warning letter sent to Procter & Gamble today concerns the same products as the letter mistakenly posted on the FDA Web site on Oct. 14, 2009, due to a computer error.)

For more information

FDA Warning Letter to Procter & Gamble
http://www.fda.gov/ICECI/EnforcementActions/WarningLetters/ucm188361.htm

FDA Drug Safety Initiative
http://www.fda.gov/cder/drugSafety.htm

Media Inquiries: Christopher Kelly, 301-796-4676, christopher.kelly@fda.hhs.gov

Consumer Inquiries: 888-INFO-FDA

SOURCE U.S. Food and Drug Administration


'/>"/>
SOURCE U.S. Food and Drug Administration
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Procter & Gamble Pharmaceuticals Launches Asacol(R) HD (mesalamine) Delayed-Release Tablets
2. Nastech Reacquires Teriparatide (Parathyroid Hormone; PTH1-34) Nasal Spray from Procter & Gamble
3. Warner Chilcott Completes Acquisition of P&Gs Global Branded Prescription Pharmaceuticals Business
4. Neuro Kinetics & Military Researchers in Push To Improve Diagnosis & Treatment of Combat Brain Injuries
5. CVS Caremarks MinuteClinic and Allina Hospitals & Clinics Form Strategic Partnership
6. Reportlinker Adds Medical Devices & Equipment in India (2009)
7. Ikaria Receives Award for Excellence by New Jersey Business & Industry Association
8. Laureate Pharma Announces Signing New Biopharmaceutical Development & Manufacturing Agreement
9. Lifesciences IT Spending to Experience Mature Growth Rates Despite Economic Slowdown, Declares Frost & Sullivan
10. MedImmune to Present Data on RSV and Influenza at 2009 American Academy of Pediatrics National Conference & Exhibition
11. Palomar to Commercialize FDA Cleared Over-The-Counter Home Use Wrinkle Treatment Laser Device Without Johnson & Johnson
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... Mass. , Feb. 9, 2016  Insulet Corporation (NASDAQ: ... tubeless insulin pump technology with its OmniPod ... David A. Lemoine has been appointed to Insulet,s Board ... of nine directors, eight of whom are independent. ... 40 years of audit and finance experience and a deep ...
(Date:2/9/2016)... February 9, 2016 ... heute den Abschluss eines Kooperationsvertrags mit 10x ... Lösungen in den Bereichen Next-Generation-Sequencing (NGS), Single-Cell-Biology ... ; Frankfurt Prime Standard: QIA) gab heute ... für die Entwicklung und Förderung umfassender Lösungen ...
(Date:2/9/2016)... Bermuda, Feb. 9, 2016  Axovant Sciences Ltd. ... on the treatment of dementia, today announced further ... cognitive, behavioral and functional aspects of Lewy body ... in the U.S. Two out of the three ... expected to start later this quarter. In addition, ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... ... AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company focused on the ... ended December 31, 2015 on Monday, February 29, 2016 after the market closes. , ... the release at 4:30 PM ET. Investors interested in participating by phone are invited ...
(Date:2/10/2016)... AZ (PRWEB) , ... February 10, 2016 , ... For ... in new book , Pioneering book "Better with Age: The Ultimate Guide to Brain ... neuroplasticity can improve memory. The book’s publication date is March 16, 2016. ...
(Date:2/10/2016)... ... February 10, 2016 , ... IDEX ... accessories. These PEEK-lined stainless steel (PLS) columns combine the strength of traditional stainless ... the integrity of biological samples while operating at ultra-high pressures of 20,000 psi. ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... The recreational ... cannabis enthusiasts in the state still face a lot of restrictions as to where ... is intended for private, personal use” and that cannabis “may not be consumed openly ...
(Date:2/10/2016)... ... 2016 , ... Ross A. Clevens, MD, FACS , ... a new addition to their growing practice. Beginning this month, Teresa Imperiale-Westerfield, a ... performing cosmetic procedures including injectables, fillers and laser treatments. A master ...
Breaking Medicine News(10 mins):